Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727693 | 1.00 | SCN4A (0.55) | SCN4AMAOAPTGS1LMNAIDO1 | |
| SCHEMBL6727689 | 1.00 | SCN4A (0.55) | SCN4AMAOAPTGS1LMNAIDO1 | |
| SCHEMBL6167803 | 0.75 | CYP2C9 (0.46) | KDM4ECYP2D6TSHRMEN1KMT2A | |
| SCHEMBL7809168 | 0.74 | LMNA (0.50) | LMNAKDM4ECYP2D6TSHRHIF1A | |
| SCHEMBL6320412 | 0.73 | TSHR (0.53) | LMNAKDM4ETSHR | |
| SCHEMBL14499008 | 0.72 | SCN4A (0.65) | SCN4AMAOAPTGS1LMNAKDM4E | |
| SCHEMBL1838875 | 0.72 | SCN4A (0.65) | SCN4AMAOAPTGS1LMNAKDM4E | |
| SCHEMBL1735295 | 0.72 | EPHX1 (0.50) | MAOAPTGS1CYP2D6 | |
| SCHEMBL1735316 | 0.72 | EPHX1 (0.50) | MAOAPTGS1CYP2D6 | |
| SCHEMBL7430414 | 0.71 | SCN4A (0.39) | SCN4AMAOAPTGS1LMNAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034222-A1 | 2,4 diamino-1,3,5-triazines, processes for their preparation and their use as herbicides and plant growth regulators | HOLLANDER JENS (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1163229-A1 | 2,4-DIAMINO-1,3,5-TRIAZINES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | Aventis CropScience GmbH (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056722-A1 | 2,4-DIAMINO-1,3,5-TRIAZINES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | AVENTIS CROPSCIENCE GMBH (DE) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034222-A1 | 2,4 diamino-1,3,5-triazines, processes for their preparation and their use as herbicides and plant growth regulators | SUB1, DDT, SAT1 | SCN4A 1383/4885MAOA 2089/4885PTGS1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.